Apotex working with FDA to resolve import alert

TORONTO The Food and Drug Administration has issued an import alert concerning products from a Canadian drug maker.

Apotex issued a statement regarding the alert, which affects drugs manufactured at two of the company’s plants and relates to observations made following audits of products destined for the United States.

“We pride ourselves on being a leading maker of top-quality generic pharmaceuticals,” Apotex president and COO Jack Kay said in a statement. “Since 1974, Apotex has produced approximately 200 billion tablets and capsules. These safe and effective products are sold in over 115 countries.”

The company said it was working with the FDA to resolve the matter.